Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Common Equity (2016 - 2025)

International Stem Cell (ISCO) has disclosed Common Equity for 16 consecutive years, with -$3.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity rose 6.56% to -$3.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$3.8 million, a 6.56% increase, with the full-year FY2024 number at -$3.9 million, up 6.14% from a year prior.
  • Common Equity was -$3.8 million for Q3 2025 at International Stem Cell, up from -$3.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of -$3.8 million in Q3 2025 to a low of -$4.7 million in Q1 2021.
  • A 5-year average of -$4.2 million and a median of -$4.3 million in 2024 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: crashed 65.25% in 2021, then rose 17.05% in 2023.
  • International Stem Cell's Common Equity stood at -$4.6 million in 2021, then grew by 1.48% to -$4.5 million in 2022, then grew by 7.37% to -$4.2 million in 2023, then rose by 6.14% to -$3.9 million in 2024, then increased by 3.92% to -$3.8 million in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Common Equity are -$3.8 million (Q3 2025), -$3.9 million (Q2 2025), and -$4.1 million (Q1 2025).